SG11201702857PA - Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy - Google Patents
Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapyInfo
- Publication number
- SG11201702857PA SG11201702857PA SG11201702857PA SG11201702857PA SG11201702857PA SG 11201702857P A SG11201702857P A SG 11201702857PA SG 11201702857P A SG11201702857P A SG 11201702857PA SG 11201702857P A SG11201702857P A SG 11201702857PA SG 11201702857P A SG11201702857P A SG 11201702857PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- cancer immunotherapy
- recombinant listeria
- vaccine strains
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063828P | 2014-10-14 | 2014-10-14 | |
| US201462065973P | 2014-10-20 | 2014-10-20 | |
| PCT/US2015/055604 WO2016061277A1 (en) | 2014-10-14 | 2015-10-14 | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702857PA true SG11201702857PA (en) | 2017-05-30 |
Family
ID=55747250
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702611YA SG11201702611YA (en) | 2014-10-14 | 2015-10-14 | Combination therapy for use in cancer therapy |
| SG10201903349YA SG10201903349YA (en) | 2014-10-14 | 2015-10-14 | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| SG11201702857PA SG11201702857PA (en) | 2014-10-14 | 2015-10-14 | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702611YA SG11201702611YA (en) | 2014-10-14 | 2015-10-14 | Combination therapy for use in cancer therapy |
| SG10201903349YA SG10201903349YA (en) | 2014-10-14 | 2015-10-14 | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10010593B2 (en) |
| EP (2) | EP3207162A4 (en) |
| JP (2) | JP2017536095A (en) |
| KR (2) | KR20170066641A (en) |
| CN (2) | CN107429289A (en) |
| AU (2) | AU2015332524A1 (en) |
| CA (2) | CA2964574A1 (en) |
| IL (2) | IL251630A0 (en) |
| MX (2) | MX2017004729A (en) |
| SG (3) | SG11201702611YA (en) |
| WO (2) | WO2016061182A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| CA2829960A1 (en) | 2011-03-11 | 2012-09-20 | John Rothman | Listeria-based adjuvants |
| AU2013232291B8 (en) | 2012-03-12 | 2016-07-21 | Advaxis, Inc. | Suppressor cell function inhibition following listeria vaccine treatment |
| KR20160130774A (en) | 2014-02-18 | 2016-11-14 | 어드박시스, 인크. | Biomarker directed multi-target immunotherapy |
| WO2015164121A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
| AU2017367642A1 (en) | 2016-11-30 | 2019-05-30 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| TW201833323A (en) * | 2017-01-05 | 2018-09-16 | 美商艾法西斯公司 | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| WO2018170313A1 (en) * | 2017-03-16 | 2018-09-20 | Advaxis, Inc. | Methods and compositions for increasing efficacy of vaccines |
| CN106978381A (en) * | 2017-03-23 | 2017-07-25 | 上海理工大学 | PrfA gene delections Listeria Monocytogenes and preparation method |
| WO2019006401A2 (en) * | 2017-06-30 | 2019-01-03 | Advaxis, Inc. | Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof |
| AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
| CN111349645B (en) * | 2018-12-24 | 2022-05-17 | 上海若泰医药科技有限公司 | Method for improving safety of non-integrated attenuated listeria vaccine |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662396B2 (en) * | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| US8114414B2 (en) * | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| CA2404164A1 (en) | 2000-03-29 | 2001-10-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| WO2003102168A1 (en) | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Attenuated listeria spp. and methods for using the same |
| US7833775B2 (en) | 2003-02-06 | 2010-11-16 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| AU2004246999B2 (en) | 2003-02-06 | 2010-06-10 | Aduro Biotech, Inc., | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
| AU2004281834A1 (en) * | 2003-10-15 | 2005-04-28 | Cerus Corporation | Listeria-based EphA2 vaccines |
| CA2577306A1 (en) * | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
| WO2007059030A2 (en) * | 2005-11-10 | 2007-05-24 | The Trustees Of The University Of Pennsylvania | Llo-encoding dna/nucleic acid vaccines and methods comprising same |
| MX2009012272A (en) * | 2007-05-15 | 2009-12-01 | Transgene Sa | Vectors for multiple gene expression. |
| US8114484B2 (en) | 2007-07-19 | 2012-02-14 | Applied Materials, Inc. | Plasma enhanced chemical vapor deposition technology for large-size processing |
| US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
| WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
| JP5998370B2 (en) * | 2010-11-17 | 2016-09-28 | アデュロ バイオテック | Methods and compositions for eliciting an immune response against EGFRVIII |
| AU2013232291B8 (en) * | 2012-03-12 | 2016-07-21 | Advaxis, Inc. | Suppressor cell function inhibition following listeria vaccine treatment |
| KR101621470B1 (en) | 2013-07-31 | 2016-05-16 | 건국대학교 산학협력단 | MoS2 thin film and preparation method thereof |
| SG11201607213QA (en) * | 2014-03-05 | 2016-09-29 | Advaxis Inc | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
| WO2015164121A1 (en) * | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
-
2015
- 2015-10-14 WO PCT/US2015/055462 patent/WO2016061182A1/en active Application Filing
- 2015-10-14 KR KR1020177012859A patent/KR20170066641A/en unknown
- 2015-10-14 MX MX2017004729A patent/MX2017004729A/en unknown
- 2015-10-14 CN CN201580056060.8A patent/CN107429289A/en active Pending
- 2015-10-14 KR KR1020177012858A patent/KR20170068560A/en unknown
- 2015-10-14 AU AU2015332524A patent/AU2015332524A1/en not_active Abandoned
- 2015-10-14 EP EP15851341.6A patent/EP3207162A4/en not_active Withdrawn
- 2015-10-14 AU AU2015333632A patent/AU2015333632A1/en not_active Abandoned
- 2015-10-14 US US14/883,557 patent/US10010593B2/en active Active
- 2015-10-14 WO PCT/US2015/055604 patent/WO2016061277A1/en active Application Filing
- 2015-10-14 EP EP15850219.5A patent/EP3207142A4/en not_active Withdrawn
- 2015-10-14 CA CA2964574A patent/CA2964574A1/en not_active Abandoned
- 2015-10-14 JP JP2017518803A patent/JP2017536095A/en active Pending
- 2015-10-14 MX MX2017004897A patent/MX2017004897A/en unknown
- 2015-10-14 US US14/882,749 patent/US20160228530A1/en not_active Abandoned
- 2015-10-14 SG SG11201702611YA patent/SG11201702611YA/en unknown
- 2015-10-14 SG SG10201903349YA patent/SG10201903349YA/en unknown
- 2015-10-14 CA CA2964764A patent/CA2964764A1/en not_active Abandoned
- 2015-10-14 CN CN201580056059.5A patent/CN107250366A/en active Pending
- 2015-10-14 JP JP2017518207A patent/JP2017532328A/en active Pending
- 2015-10-14 SG SG11201702857PA patent/SG11201702857PA/en unknown
-
2017
- 2017-04-06 IL IL251630A patent/IL251630A0/en unknown
- 2017-04-06 IL IL251624A patent/IL251624A0/en unknown
-
2018
- 2018-07-02 US US16/025,952 patent/US20190030145A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170066641A (en) | 2017-06-14 |
| MX2017004897A (en) | 2018-02-09 |
| EP3207162A1 (en) | 2017-08-23 |
| WO2016061277A1 (en) | 2016-04-21 |
| MX2017004729A (en) | 2018-01-09 |
| US20190030145A1 (en) | 2019-01-31 |
| IL251624A0 (en) | 2017-06-29 |
| AU2015333632A1 (en) | 2017-06-01 |
| EP3207142A1 (en) | 2017-08-23 |
| AU2015332524A1 (en) | 2017-06-01 |
| US10010593B2 (en) | 2018-07-03 |
| JP2017532328A (en) | 2017-11-02 |
| EP3207142A4 (en) | 2018-07-04 |
| SG11201702611YA (en) | 2017-04-27 |
| KR20170068560A (en) | 2017-06-19 |
| US20160367650A1 (en) | 2016-12-22 |
| CA2964764A1 (en) | 2016-04-21 |
| WO2016061182A1 (en) | 2016-04-21 |
| IL251630A0 (en) | 2017-06-29 |
| SG10201903349YA (en) | 2019-05-30 |
| CA2964574A1 (en) | 2016-04-21 |
| CN107250366A (en) | 2017-10-13 |
| CN107429289A (en) | 2017-12-01 |
| JP2017536095A (en) | 2017-12-07 |
| EP3207162A4 (en) | 2018-07-04 |
| US20160228530A1 (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251624A0 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| IL258563A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| IL248483A0 (en) | Recombinant listeria vaccine strains and methods of producing the same | |
| HK1243102A1 (en) | Anti-cd79b antibodies and methods of use | |
| IL258004A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| HRP20181359T1 (en) | Anti-jagged1 antibodies and methods of use | |
| IL247066A0 (en) | Immunotherapy of cancer through combination of local and systemic immune stimulation | |
| SG10202001485UA (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| EP3142496A4 (en) | Direct-fed microbials and methods of their use | |
| IL248399A0 (en) | Novel antii-rnf43 antibodies and methods of use | |
| IL247754A0 (en) | Anti-mcam antibodies and associated methods of use | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| ZA201701674B (en) | Novel anti-mfi2 antibodies and methods of use | |
| EP3215602A4 (en) | Methods and materials for producing recombinant viruses in eukaryotic microalgae | |
| HK1246181A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| GB201416293D0 (en) | Methods and preparations | |
| ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
| IL287985A (en) | Koc1-derived peptide and vaccine including same | |
| HK1244534A1 (en) | Recombinant borrelia proteins and methods of use thereof | |
| IL250215A0 (en) | Cdca1-derived peptide and vaccine containing same | |
| IL247448A0 (en) | Peptides and methods of use | |
| IL250235A0 (en) | Urlc10-derived peptide and vaccine containing same |